20/15 Visioneers’ Post

View organization page for 20/15 Visioneers, graphic
20/15 Visioneers

3,365 followers

Don't miss out! Learn about Scilligence's RegMol during Amjad Nasir's presentation on Tuesday, February 27th. Talk Abstract: The pharmaceutical industry is transitioning from traditional Small Molecule therapeutics to Biologics-based therapeutics (antibodies, proteins, oligonucleotides and peptides, etc.). At Scilligence, our goal is to provide the scientist with a unified informatics platform that embraces multi-modal entities - RegMol is a Registration and Assay Management system that enables scientists to do just that. Users can register antibody-drug conjugates, peptides, oligonucleotides, and LNPs, to name a few. RegMol also automatically tracks the relationships between all of these registered entities - this enables the User to have a comprehensive overview of how Entities are linked to each other. RegMol's architecture enables Users to configure registration forms to suit their workflows and thereby evolve to meet their scientific needs in a single system without the need for any custom code.   #entityregistration #scienceandtechnology #freeevent https://lnkd.in/esJGBbrc

Best of the Best Entity Registration | 20/15 Visioneers

Best of the Best Entity Registration | 20/15 Visioneers

20visioneers15.com

20/15 Visioneers

7mo

Hi Everyone! The webinar will start in about 15 minutes. Hope to see you there.

Like
Reply
20/15 Visioneers

7mo

Looking forward to this Amjad Nasir!

Like
Reply
See more comments

To view or add a comment, sign in

More Relevant Posts

  • View profile for John F. Conway, graphic
    John F. Conway

    Science and Technology Visioneering, Cloud Lab/HTE/HPC Evangelist, Informatics & New Modalities, InSilico-First with Model-Quality Data, Reproducibility and Replication, Marketing (Webinartist), and Strategic Staffing.

    Hey Discovery Scientists, come hear what Amjad Nasir has to say about Scientific Entity Registration! #researchanddevelopment #scientificinformatics #chemistry #biology

    View organization page for 20/15 Visioneers, graphic
    20/15 Visioneers

    3,365 followers

    Don't miss out! Learn about Scilligence's RegMol during Amjad Nasir's presentation on Tuesday, February 27th. Talk Abstract: The pharmaceutical industry is transitioning from traditional Small Molecule therapeutics to Biologics-based therapeutics (antibodies, proteins, oligonucleotides and peptides, etc.). At Scilligence, our goal is to provide the scientist with a unified informatics platform that embraces multi-modal entities - RegMol is a Registration and Assay Management system that enables scientists to do just that. Users can register antibody-drug conjugates, peptides, oligonucleotides, and LNPs, to name a few. RegMol also automatically tracks the relationships between all of these registered entities - this enables the User to have a comprehensive overview of how Entities are linked to each other. RegMol's architecture enables Users to configure registration forms to suit their workflows and thereby evolve to meet their scientific needs in a single system without the need for any custom code.   #entityregistration #scienceandtechnology #freeevent https://lnkd.in/esJGBbrc

    Best of the Best Entity Registration | 20/15 Visioneers

    Best of the Best Entity Registration | 20/15 Visioneers

    20visioneers15.com

    To view or add a comment, sign in

  • View profile for Margaret Brown, graphic
    Margaret Brown

    Sales Revvity Signals

    Signals Synergy is a game-changer in the biopharma space. Check out our blog on how this dedicated informatics solution enables seamless collaboration between biopharma sponsors and contract partners, helping to accelerate the drug discovery process: https://lnkd.in/giww7Xng

    • No alternative text description for this image

    To view or add a comment, sign in

  • View organization page for TrialHub, graphic
    TrialHub

    3,364 followers

    Where are the eligible patients who will benefit from your clinical trial? 👉 This is the most important question you need to start with if you want to avoid costly amendments that will slow you down. AICROS now answers this question in seconds - with TrialHub's Standard of Care and feasibility intelligence. So when they reach out to their local colleagues, they do so prepared with very specific questions. ⌛ Ultimately, this saves them hundreds of hours on trial planning. Let's celebrate them together as the #InnovativeLeader they are! #clinicalresearch #clinicaltrials #pharma #biotech #standardofcare

    To view or add a comment, sign in

  • View organization page for Worldwide Clinical Trials, graphic
    Worldwide Clinical Trials

    170,461 followers

    As clinical research continues to evolve, drug repurposing will play a critical role in addressing unmet needs faster and more effectively than the traditional drug development model. Learn more about how drug repurposing can help you reduce the cost and complexity of drug development in our white paper: https://ow.ly/gNbo50Ql7vz

    The Utility of Drug Repurposing in Orphan Disease Research

    The Utility of Drug Repurposing in Orphan Disease Research

    To view or add a comment, sign in

  • View profile for Mary P., graphic
    Mary P.

    Senior Field Scientist @ Revvity | Molecular Diagnostics, Biotech

    Signals Synergy is a game-changer in the biopharma space. Check out our blog on how this dedicated informatics solution enables seamless collaboration between biopharma sponsors and contract partners, helping to accelerate the drug discovery process: https://lnkd.in/gbXVtszy

    • No alternative text description for this image

    To view or add a comment, sign in

  • View profile for Mattew Sameh Hezkial, graphic
    Mattew Sameh Hezkial

    Technical Support Manager at Nozha Trading Organization

    Analytical tools in small molecule drug development

    View organization page for Malvern Panalytical Pharmaceuticals, graphic
    Malvern Panalytical Pharmaceuticals

    15,827 followers

    If you work in small molecule drug development (SMD), you can still sign up for our in-person workshop on June 13 2024, held in Somerset, New Jersey! But don’t miss out – attendance is limited to 30 participants, hurry up, only few spots available ❗️⏳ In collaboration with NETZSCH Group and SOTAX Group, we bring you the latest developments in SMD tools. Learn from top experts, and network with others involved in your field! Through a series of in-depth talks on topics such as polymorph identification and crystallinity, particle sizing, dosage form development, analytical methods for OINDP and ophthalmic formulations and thermal analysis/rheology, the agenda is packed with topics that will provide insight into the current challenges facing the development of small molecule APIs into drugs. 💊 Check the agenda, and register now clicking on the snippet and title below⬇️ June 13, 2024 📍16 Cedar Grove Ln, Somerset, New Jersey 08873, United States of America 🕣 9:00 – 4:00 EDT 👩🔬 In person #MalvernPanalytical #DrugDiscovery #Workshop #Pharma

    Analytical Tools in Small Molecule Drug Development

    Analytical Tools in Small Molecule Drug Development

    events.malvernpanalytical.com

    To view or add a comment, sign in

  • View profile for Dalma Ferenczi MBA, graphic
    Dalma Ferenczi MBA

    Providing best in class cheminformatics solutions and services for the pharma and biotech industry

    Chemaxon and Certara finally as one company, bringing you the next generation of a more precise, model-informed Drug Discovery and Development, with improved certainty in decision-making throughout. Join us for a live webinar on 20th Nov with Certara's CEO William Feehery and Chemaxon's CEO Richard Jones to learn more and be sure to check out our press release below

    View organization page for Chemaxon, graphic
    Chemaxon

    7,204 followers

    Chemaxon and Certara are now bonded! Together we are transforming drug discovery and development bringing the next generation of medicines to patients faster and with greater certainty.   “Together, we will offer clients the ability to broadly conduct in-silico research to inform better decision-making at every phase of development.” Richard Jones, Chemaxon’s CEO. Learn more about the news directly from Certarta CEO William Feehery and Chemaxon CEO Richard Jones when they will share what is next at this Nasdaq sponsored webinar Nov 20: https://lnkd.in/gW-jTP7W Read the press release for more details: https://lnkd.in/gkWF_Bfm

    To view or add a comment, sign in

20/15 Visioneers

3,365 followers

View Profile

Explore topics